Regulatory Information
GLAXOSMITHKLINE PTE LTD
GLAXOSMITHKLINE PTE LTD
Therapeutic
Prescription Only
Formulation Information
POWDER, METERED
**Dosage and Administration** Seretide Accuhaler is for oral inhalation only. Patients should be made aware that Seretide Accuhaler must be used regularly for optimum benefit, even when asymptomatic. Patients should be regularly reassessed by a doctor, so that the strength of Seretide they are receiving remains optimal and is only changed on medical advice. **Asthma** The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. Patients should be given the strength of Seretide containing the appropriate fluticasone propionate dosage for the severity of their disease. If a patient is inadequately controlled on inhaled corticosteroid therapy alone, substitution with Seretide at a therapeutically equivalent corticosteroid dose may result in an improvement in asthma control. Recommended Doses: Adults and adolescents 12 years and older: One inhalation (50 mcg salmeterol and 100 mcg fluticasone propionate) twice daily. or One inhalation (50 mcg salmeterol and 250 mcg fluticasone propionate) twice daily. or One inhalation (50 mcg salmeterol and 500 mcg fluticasone propionate) twice daily. Children 4 years and older: One inhalation (50 mcg salmeterol and 100 mcg fluticasone propionate) twice daily. There are no data available for use of Seretide in children aged under 4 years. **Chronic Obstructive Pulmonary Disease (COPD)** For adult patients, the recommended dose is one inhalation (50 mcg salmeterol and 500 mcg fluticasone propionate) twice daily. **Special patient groups** There is no need to adjust the dose in elderly patients or in those with renal or hepatic impairment.
RESPIRATORY (INHALATION)
Medical Information
**Indications** Pharmaceutical form: Inhalation powder. Seretide is indicated in the regular treatment of asthma where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. Seretide is indicated for the symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
**Contraindications** Seretide is contraindicated in patients with a history of hypersensitivity to any of the ingredients. Seretide Accuhaler is contraindicated in patients with severe milk protein allergy.
R03AK06
salmeterol and fluticasone
Manufacturer Information
GLAXOSMITHKLINE PTE LTD
GlaxoSmithKline LLC
Active Ingredients
Documents
Package Inserts
Seretide Accuhaler PI.pdf
Approved: April 12, 2021